{"schema_version":"secwatch.filing_event.v1","accession":"0001645113-23-000022","form_type":"8-K","ticker":"NVCR","cik":"0001645113","company_name":"NovoCure Ltd","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.982619+00:00","generated_at":"2026-06-19T02:46:53.441469+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"NovoCure Q4 2022 net revenues $128.4M, full year $537.8M; LUNAR study meets primary endpoint","bullets":["Full year 2022 net revenues $537.8M (+1% YoY); Q4 net revenues $128.4M (-4% YoY).","Q4 net loss $37.3M ($0.36 loss per share); adjusted EBITDA $(10.5)M.","Active patients 3,430 as of Dec 31, 2022 (-4% YoY); prescriptions 1,373 in Q4 (-4% YoY).","Pivotal LUNAR study in NSCLC met primary overall survival endpoint; PANOVA-3 enrollment completed.","Elected Dr. Allyson J. Ocean to Board of Directors; CE Mark for new array, limited market release in Europe."],"urls":{"canonical":"https://secwatch.observer/filing/0001645113-23-000022","json":"https://secwatch.observer/filing/0001645113-23-000022.json","markdown":"https://secwatch.observer/filing/0001645113-23-000022.md","text":"https://secwatch.observer/filing/0001645113-23-000022.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000022/0001645113-23-000022-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000022/nvcr-20230223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T02:46:53.441469+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2a85063485b47a965dc12f28aef6b900751213a7","claim":"NovoCure Ltd reported the fourth quarter ended December 31, 2022 results: revenue $128.4 million, net income $37.3 million, EPS $0.36 per share.","evidence_excerpt":"Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Company Update Full year 2022 net revenues of $538 million and fourth quarter net revenues of $128 million Pivotal LUNAR study in non-small cell lung cancer met primary overall survival endpoint and a key secondary overall survival endpoint Novocure completes enrollment of the pivotal","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000022/0001645113-23-000022-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$128.4 million"},{"label":"Net income","value":"$37.3 million"},{"label":"EPS","value":"$0.36 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"df63b2807968a1feda12be2368041410f598ca68","claim":"NovoCure Ltd reported the fiscal year ended December 31, 2022 results: revenue $537.8 million.","evidence_excerpt":"Total net revenues for the year were $537.8 million, an increase of 1% year-over-year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1645113/000164511323000022/0001645113-23-000022-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2022"},{"label":"Revenue","value":"$537.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}